QCG
KLRS

Quadrant Capital Group’s Kalaris Therapeutics KLRS Stock Holding History

Quadrant Capital Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-132
Closed -$6.51K – 2796
2023
Q3 		$6.51K Buy
+132
New +$8.99K ﹤0.01% 2105
2023
Q2 		– Sell
-15
Closed -$1.37K – 2787
2023
Q1 		$1.37K Sell
15
-15
-50% -$1.91K ﹤0.01% 2492
2022
Q4 		$3.54K Buy
30
+15
+100% +$2.54K ﹤0.01% 2288
2022
Q3 		$3K Buy
+15
New +$2.34K ﹤0.01% 2311

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Quadrant Capital Group's KLRS Position: Q4 2023 in Review

Quadrant Capital Group sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 132 shares — an estimated $6.51K sold.

Quadrant Capital Group first reported a position in KLRS in Q3 2022 and held it in 4 quarters. The position peaked at $6.51K in Q3 2023. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Quadrant Capital Group reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 132 Kalaris Therapeutics shares in Q4 2023, an estimated $6.51K.
  • Quadrant Capital Group first reported a position in Kalaris Therapeutics in Q3 2022 and held it in 4 quarters.
  • Quadrant Capital Group's Kalaris Therapeutics position peaked at $6.51K in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Quadrant Capital Group's 13F filing for Q4 2023, filed 8 Feb 2024.